ArticlePediatric research2026
Dexmedetomidine use in Infants undergoing Cooling due to neonatal Encephalopathy (DICE trial): safety and pharmacokinetics.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundInfants undergoing therapeutic hypothermia (TH) due to neonatal encephalopathy often require sedation and pain medication. Dexmedetomidine may be a good alternative to morphine as it provides both sedation and analgesia. However, the safety and pharmacokinetics (PK) of dexmedetomidine in this population are not well established.
methodsIn this Phase II, multicenter, open-label, randomized, safety and PK trial, 48 infants undergoing TH for encephalopathy were randomized to receive dexmedetomidine (25) or morphine (23) using standardized doses. PK parameters of dexmedetomidine in this population were calculated using a nonlinear mixed effects modeling using NONMEM
resultsThere were no statistically significant differences between groups in baseline characteristics, hospitalization outcomes and adverse events. A total of 315 dexmedetomidine PK samples using a 1-compartment model with first-order elimination analysis were analyzed. Median clearance and volume of distribution were 0.51 L/kg/h and 0.25 L/kg. Weight, post-menstrual age, maximum liver enzymes, and encephalopathy severity influenced dexmedetomidine PK.
conclusionThe incidence of adverse events and hospitalization outcomes in infants randomized to dexmedetomidine or morphine during hypothermia were similar. Using population PK to model dexmedetomidine, lower clearance and volume of distribution parameters were found in infants undergoing hypothermia compared to previously published parameters in non-cooled infants. IMPACT: Infants undergoing therapeutic hypothermia for encephalopathy often require drugs to treat pain and for sedation in the intensive care unit. Dexmedetomidine may be a better alternative to opiates since it provides sedation, analgesia, and prevents shivering but does not suppress ventilation. In this randomized, unmasked, safety and PK trial we found no significant differences in short term hospital outcomes and incidence of adverse events in infants receiving dexmedetomidine when compared to infants receiving morphine. The pharmacokinetics of dexmedetomidine in this at-risk population was further established.
Identifiers
42304121What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.